Huiqing Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Huiqing Xu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Yingjun Li
School of Public Health, Hangzhou Medical College, Hangzhou 310013, China; Key Discipline of Zhejiang Province in Public Health and Preventative Medicine (First Class, Category A), Hangzhou Medical College, Hangzhou, China
2 shared publications - Dan Zhou
Zhejiang University School of Medicine
1 shared publication - Fei Xu
Nanjing Medical University Affiliated Nanjing Municipal Center for Disease Control and Prevention
1 shared publication - Guofeng Ao
Nanjing Municipal Center for Disease Control and Prevention, Affiliated Nanjing Medical University, Nanjing, China
1 shared publication Han Jiang
School of Public Health, Hangzhou Medical College, Hangzhou, CHINA
1 shared publication- James T. Elder
Department of Dermatology, University of Michigan Medical School, Ann Arbor, USA
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Korean Society for Preventive Medicine in Journal of Preventive Medicine and Public Health
- Vol. 59 (5) , 476-488
Global, Regional, and National Burden of Heart Failure Attributable to Chronic Obstructive Pulmonary Disease From 1990 to 2021, With Projections to 2050
Objectives: Heart failure (HF), a common comorbidity of chronic obstructive pulmonary disease (COPD), is associated with an increased risk of death among patients with COPD. However, no systematic assessment has quantified the population-level burden of comorbid COPD and HF, worldwide. This study assessed the global, regional, and national HF burden attributable to COPD from 1990 to 2021 and projected this burden to 2050.Methods: Data on the non-fatal burden of COPD-attributable HF, including prevalence and years lived with disability (YLDs), were obtained from the Global Burden of Disease Study 2021. Temporal trends in age-standardized rates (ASRs) for COPD-attributable HF from 1990 to 2021 were examined using joinpoint models. Bayesian age-period-cohort models were used to project ASRs to 2050.Results: From 1990 to 2021, the absolute numbers of prevalent cases and YLDs for COPD-attributable HF increased globally, and the ASRs for prevalence and YLDs also increased. These upward trends were projected to continue to 2050. The burden of HF attributable to COPD was consistently higher in males than in females and higher in older adults than in younger individuals. By severity level, the burden of HF attributable to COPD was mainly driven by the treated and severe subtypes of HF. The burden varied substantially across regions, with low-socio-demographic index regions had the highest age-standardized burden.Conclusions: The global non-fatal burden of HF attributable to COPD was substantial from 1990 to 2021 and may continue to increase to 2050. Public health interventions targeting HF attributable to COPD may help reduce this burden.
- 30 September 2026
- Published by Korean Society for Preventive Medicine in Journal of Preventive Medicine and Public Health
- Vol. 59 (5) , 476-488
Open AccessGlobal, Regional, and National Burden of Heart Failure Attributable to Chronic Obstructive Pulmonary Disease From 1990 to 2021, With Projections to 2050
Objectives: Heart failure (HF), a common comorbidity of chronic obstructive pulmonary disease (COPD), is associated with an increased risk of death among patients with COPD. However, no systematic assessment has quantified the population-level burden of comorbid COPD and HF, worldwide. This study assessed the global, regional, and national HF burden attributable to COPD from 1990 to 2021 and projected this burden to 2050.Methods: Data on the non-fatal burden of COPD-attributable HF, including prevalence and years lived with disability (YLDs), were obtained from the Global Burden of Disease Study 2021. Temporal trends in age-standardized rates (ASRs) for COPD-attributable HF from 1990 to 2021 were examined using joinpoint models. Bayesian age-period-cohort models were used to project ASRs to 2050.Results: From 1990 to 2021, the absolute numbers of prevalent cases and YLDs for COPD-attributable HF increased globally, and the ASRs for prevalence and YLDs also increased. These upward trends were projected to continue to 2050. The burden of HF attributable to COPD was consistently higher in males than in females and higher in older adults than in younger individuals. By severity level, the burden of HF attributable to COPD was mainly driven by the treated and severe subtypes of HF. The burden varied substantially across regions, with low-socio-demographic index regions had the highest age-standardized burden.Conclusions: The global non-fatal burden of HF attributable to COPD was substantial from 1990 to 2021 and may continue to increase to 2050. Public health interventions targeting HF attributable to COPD may help reduce this burden.
- 1 November 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (5) , 684-691
Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study
Background: Alcohol consumption and smoking have been reported to be associated with psoriasis risk. However, a conclusion with high-quality evidence of causality could not be easily drawn from regular observational studies. Objectives: This study aims to assess the causal associations of alcohol consumption and smoking with psoriasis. Methods: Genome-wide association study (GWAS) summary-level data for alcohol consumption (N = 941 280), smoking initiation (N = 1 232 091), cigarettes per day (N = 337 334) and smoking cessation (N = 547 219) was obtained from the GSCAN consortium (Sequencing Consortium of Alcohol and Nicotine use). The GWAS results for lifetime smoking (N = 462 690) were obtained from the UK Biobank samples. Summary statistics for psoriasis were obtained from a recent GWAS meta-analysis of eight cohorts comprising 19 032 cases and 286 769 controls and the FinnGen consortium, comprising 4510 cases and 212 242 controls. Linkage disequilibrium score regression was applied to compute the genetic correlation. Bidirectional Mendelian randomization (MR) analyses were conducted to determine casual direction using independent genetic variants that reached genome-wide significance (P < 5 × 10–8). Results: There were genetic correlations between smoking and psoriasis. MR revealed a causal effect of smoking initiation [odds ratio (OR) 1·46, 95% confidence interval (CI) 1·32–1·60, P = 6·24E-14], cigarettes per day (OR 1·38, 95% CI 1·13–1·67, P = 0·001) and lifetime smoking (OR 1·96, 95% CI 1·41–2·73, P = 7·32E-05) on psoriasis. Additionally, a suggestive causal effect of smoking cessation on psoriasis was observed (OR 1·39, 95% CI 1·07–1·79, P = 0·012). We found no causal relationship between alcohol consumption and psoriasis (P = 0·379). The reverse associations were not statistically significant. Conclusions: Our findings provide causal evidence for the effects of smoking on psoriasis risk. What is already known about this topic? Alcohol consumption and smoking have been reported to be associated with psoriasis risk.Whether alcohol consumption and smoking have a causal effect on psoriasis risk remains unclear. What does this study add? This Mendelian randomization study shows a causal association between smoking, but not alcohol consumption, and the risk of developing psoriasis.Restricting smoking could be helpful in reducing the burden of psoriasis.
- 1 November 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (5) , 684-691
Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study
Background: Alcohol consumption and smoking have been reported to be associated with psoriasis risk. However, a conclusion with high-quality evidence of causality could not be easily drawn from regular observational studies. Objectives: This study aims to assess the causal associations of alcohol consumption and smoking with psoriasis. Methods: Genome-wide association study (GWAS) summary-level data for alcohol consumption (N = 941 280), smoking initiation (N = 1 232 091), cigarettes per day (N = 337 334) and smoking cessation (N = 547 219) was obtained from the GSCAN consortium (Sequencing Consortium of Alcohol and Nicotine use). The GWAS results for lifetime smoking (N = 462 690) were obtained from the UK Biobank samples. Summary statistics for psoriasis were obtained from a recent GWAS meta-analysis of eight cohorts comprising 19 032 cases and 286 769 controls and the FinnGen consortium, comprising 4510 cases and 212 242 controls. Linkage disequilibrium score regression was applied to compute the genetic correlation. Bidirectional Mendelian randomization (MR) analyses were conducted to determine casual direction using independent genetic variants that reached genome-wide significance (P < 5 × 10–8). Results: There were genetic correlations between smoking and psoriasis. MR revealed a causal effect of smoking initiation [odds ratio (OR) 1·46, 95% confidence interval (CI) 1·32–1·60, P = 6·24E-14], cigarettes per day (OR 1·38, 95% CI 1·13–1·67, P = 0·001) and lifetime smoking (OR 1·96, 95% CI 1·41–2·73, P = 7·32E-05) on psoriasis. Additionally, a suggestive causal effect of smoking cessation on psoriasis was observed (OR 1·39, 95% CI 1·07–1·79, P = 0·012). We found no causal relationship between alcohol consumption and psoriasis (P = 0·379). The reverse associations were not statistically significant. Conclusions: Our findings provide causal evidence for the effects of smoking on psoriasis risk. What is already known about this topic? Alcohol consumption and smoking have been reported to be associated with psoriasis risk.Whether alcohol consumption and smoking have a causal effect on psoriasis risk remains unclear. What does this study add? This Mendelian randomization study shows a causal association between smoking, but not alcohol consumption, and the risk of developing psoriasis.Restricting smoking could be helpful in reducing the burden of psoriasis.
- Open Access
- 25 August 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 892742
Osteoarthritis, coronary artery disease, and myocardial infarction: A mendelian randomization study
Background: Observational studies indicate that osteoarthritis (OA) and coronary artery disease (CAD), as well as myocardial infarction (MI), are often diagnosed as comorbid diseases. We performed a bidirectional Mendelian randomization (MR) study to demonstrate whether there is a causal relationship between OA, CAD, and MI.Methods: We extracted single nucleotide polymorphisms (SNPs) related to OA in the Genetics of Osteoarthritis (GO) Consortium as instrumental variables to assess whether OA is associated with CAD and MI in the CARDIoGRAMplusC4D 1,000 Genomes genome-wide association study (GWAS). In the reverse MR, we used CAD-associated and MI-associated SNPs to the GWAS of OA to analyze their causality. These GWASs included 766,690 individuals of OA, 184,305 individuals of CAD, and 166,065 individuals of MI. MR was conducted using several methods, including the inverse variance weighted (IVW) method, the weighted median method, the MR-Egger method, and the MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method.Results: The forward causal effect of OA on CAD and MI was not observed. In reverse analysis, no causal effect was discovered for CAD on the risk of OA. Notably, we observed a causal association between MI and total OA [IVW odds ratio (OR) = 0.95, 95% CI = 0.93, 0.98, P = 4E−04] and spine OA (IVW OR = 0.92, 95% CI = 0.88, 0.97, P = 0.001) but a null association between MI and knee OA, hip OA, hand OA, and thumb OA.Conclusion: This MR study identifies a potentially protective effect of genetically predicted MI on total and spine OA risks.
- 25 August 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 892742
Open AccessOsteoarthritis, coronary artery disease, and myocardial infarction: A mendelian randomization study
Background: Observational studies indicate that osteoarthritis (OA) and coronary artery disease (CAD), as well as myocardial infarction (MI), are often diagnosed as comorbid diseases. We performed a bidirectional Mendelian randomization (MR) study to demonstrate whether there is a causal relationship between OA, CAD, and MI.Methods: We extracted single nucleotide polymorphisms (SNPs) related to OA in the Genetics of Osteoarthritis (GO) Consortium as instrumental variables to assess whether OA is associated with CAD and MI in the CARDIoGRAMplusC4D 1,000 Genomes genome-wide association study (GWAS). In the reverse MR, we used CAD-associated and MI-associated SNPs to the GWAS of OA to analyze their causality. These GWASs included 766,690 individuals of OA, 184,305 individuals of CAD, and 166,065 individuals of MI. MR was conducted using several methods, including the inverse variance weighted (IVW) method, the weighted median method, the MR-Egger method, and the MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) method.Results: The forward causal effect of OA on CAD and MI was not observed. In reverse analysis, no causal effect was discovered for CAD on the risk of OA. Notably, we observed a causal association between MI and total OA [IVW odds ratio (OR) = 0.95, 95% CI = 0.93, 0.98, P = 4E−04] and spine OA (IVW OR = 0.92, 95% CI = 0.88, 0.97, P = 0.001) but a null association between MI and knee OA, hip OA, hand OA, and thumb OA.Conclusion: This MR study identifies a potentially protective effect of genetically predicted MI on total and spine OA risks.